Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy-Reference-Cited by-同舟云学术

Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy

Published:2020-06-09 Issue:17 Volume:126 Page:3950-3960
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

McIntosh Andrew G.¹^ORCID,Umbreit Eric C.¹,Holland Levi C.¹^ORCID,Gu Cindy¹,Tannir Nizar M.²,Matin Surena F.¹,Karam Jose A.¹³^ORCID,Culp Stephen H.⁴,Wood Christopher G.¹

Affiliation:

1. Department of Urology Division of Surgery The University of Texas MD Anderson Cancer Center Houston TexasUSA

2. Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston TexasUSA

3. Department of Molecular and Translational Pathology The University of Texas MD Anderson Cancer Center Houston TexasUSA

4. Department of Urology University of Virginia Health System Charlottesville VirginiaUSA

Funder

University of Texas MD Anderson Cancer Center

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32991

Reference30 articles.

1. Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

2. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

3. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation

4. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

5. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review;Future Oncology;2024-09-11

2. Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN);Clinical Genitourinary Cancer;2024-07

3. Development of a Nomogram Model to Identify Appropriate Candidates from Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Based on the Surveillance, Epidemiology and End Results Database;Clinical Genitourinary Cancer;2024-06

4. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database;PLOS ONE;2024-03-28

5. Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis;JNCI: Journal of the National Cancer Institute;2024-03-14